Last reviewed · How we verify

NCT04747093

Induced-T Cell Like NK Cells for B Cell Malignancies

Status unknown Phase 1, PHASE2 Last updated 10 February 2021
What this trial tests

Phase 1, PHASE2 trial testing CAR-ITNK cells in B Cell Leukemia in 12 participants. Status unknown.

Timeline
29 January 2021
Primary endpoint
31 December 2021
31 March 2022

Quick facts

Lead sponsorNanfang Hospital, Southern Medical University
PhasePhase 1, PHASE2
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment12
Start date29 January 2021
Primary completion31 December 2021
Estimated completion31 March 2022
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Nanfang Hospital, Southern Medical University

Who can join

Adults 18 to 65, any sex, with B Cell Leukemia or B Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Relapsed and refractory B cell malignancies show unfavorable prognosis, especially for adult patients. Now, there is no standard management for these patients. Induced-T cell-like NK cells with chimeric antigen receptor (CAR-ITNK cells) is a promising treatment option for treating B cell derived malignancy. The purpose of this study is to evaluate the efficacy and safety of CAR-ITNK cells infusions in patients with relapsed and refractory B cell malignancies.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Exploring treatment options in cancer: Tumor treatment strategies.
    Liu B, Zhou H, Tan L, Siu KTH, et al · · 2024 · cited 536× · PMID 39013849 · DOI 10.1038/s41392-024-01856-7
  2. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
    Pan K, Farrukh H, Chittepu VCSR, Xu H, et al · · 2022 · cited 478× · PMID 35361234 · DOI 10.1186/s13046-022-02327-z
  3. Development of NK cell-based cancer immunotherapies through receptor engineering.
    Page A, Chuvin N, Valladeau-Guilemond J, Depil S. · · 2024 · cited 123× · PMID 38443448 · DOI 10.1038/s41423-024-01145-x
  4. The clinical landscape of CAR NK cells.
    Jørgensen LV, Christensen EB, Barnkob MB, Barington T. · · 2025 · cited 61× · PMID 40149002 · DOI 10.1186/s40164-025-00633-8
  5. Preclinical and clinical studies of CAR-NK-cell therapies for malignancies.
    Li H, Song W, Li Z, Zhang M. · · 2022 · cited 56× · PMID 36353643 · DOI 10.3389/fimmu.2022.992232
  6. Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside.
    Zhang B, Yang M, Zhang W, Liu N, et al · · 2024 · cited 50× · PMID 38221520 · DOI 10.1038/s41419-024-06438-7
  7. Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond.
    Shin E, Bak SH, Park T, Kim JW, et al · · 2023 · cited 46× · PMID 37539051 · DOI 10.3389/fimmu.2023.1192907
  8. CAR-NK as a Rapidly Developed and Efficient Immunotherapeutic Strategy against Cancer.
    Włodarczyk M, Pyrzynska B. · · 2022 · cited 35× · PMID 36612114 · DOI 10.3390/cancers15010117

Verify or expand the search:

Other recruiting trials for B Cell Leukemia

Currently open trials in the same condition.

Other Nanfang Hospital, Southern Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04747093.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing